BackTable Vascular & Interventional Ep. 589 Lung Cancer Tumor Boards: Multidisciplinary Approaches & Best Practices with Dr. Karen Reckamp, Dr. Scott Atay, Dr. Scott Oh, Dr. Alan Lee
Nov 14, 2025
Dr. Karen Reckamp, a thoracic oncologist, joins Dr. Alan Lee, a radiation oncologist, Dr. Scott Atay, a thoracic surgeon, and Dr. Scott Oh, an interventional pulmonologist, for a rich discussion on lung cancer management. They explore the dynamics of tumor boards, emphasizing collaborative decision-making and the benefits of hybrid meetings post-COVID. The panel dives into the significance of tissue diagnosis, mediastinal staging, and the evolving role of ablation therapy, highlighting challenges and strategies in treating early-stage and metastatic lung cancer.
AI Snips
Chapters
Transcript
Episode notes
Hybrid Tumor Boards Expand Access
- Virtual or hybrid tumor boards expanded access and continuity across community sites after COVID.
- They allow more treating physicians to engage in multidisciplinary planning for lung cancer care.
Web Meetings Lose Informal Collaboration
- Virtual meetings reduce informal conversations and weaken personal connections between specialists.
- Those lost interactions make it harder to reach collaborative decisions or to casually consult colleagues on complex cases.
Bring Early-Stage Cases To Tumor Board
- Bring all early-stage cases to tumor board because multiple specialties may offer different curative or trial options.
- Discuss trial eligibility, radiation, ablation, and operability before choosing treatment.